Venture Kick

Unomr develops nano-micro technology-based sensing approaches for diagnostics and drug discovery. It has a single-molecule protein modification sensor that analyzes unknown protein properties and glycosylation, supported by hardware and software for in-depth proteomics analysis using serial nanopore sensing. The technologies enable researchers across academic, biotechnology, and pharmaceutical development to advance protein characterization and product value.

REMUUN is a biotechnology company focused on revolutionizing the development of therapeutic antibodies. It has created the MEGA platform, which mimics natural antibody gene modification and employs AID-based gene editing. This technology enables clients to accelerate, reduce costs, and enhance precision in the creation of monoclonal antibody therapies.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases

BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments

Shape Biopharmaceuticals is a biotechnology company that specializes in the development of immunotherapeutic drugs aimed at treating chronic diseases with limited treatment options. The company focuses on advanced protein design and formulation technologies to create a new generation of immunotherapies. By addressing unmet medical needs, Shape Biopharmaceuticals seeks to improve patient outcomes for individuals with genetically driven conditions who lack effective therapeutic alternatives. Through its innovative healthcare solutions, the company aims to provide hope and enhance treatment possibilities for patients facing significant health challenges.

Nerai Bio is a biotechnology company that specializes in advancing genetic therapies. It operates an AI-assisted CRISPR protein engineering platform, enabling clients to enhance the development of next-generation therapeutic systems.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Translation-X is a biotechnology company specializing in the development of innovative therapeutics for Autism Spectrum Disorders (ASD). It employs a precision medicine strategy to target core symptoms of ASD, such as social interaction difficulties, aiming to provide effective treatment options for affected individuals.

ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.

Abrinca Genomics is a biotechnology company specializing in the development of a web-based platform for managing and analyzing microbial genomics data. The platform is designed to be self-hosted, scalable, and dataset-independent, allowing researchers and bioinformaticians to securely organize, explore, and analyze vast volumes of microbial genome data. It supports multiple annotation formats, offers flexible access controls, and integrates seamlessly into existing workflows.

Amporin Pharmaceuticals seeks to create a new class of small-molecule medications that block and eradicate harmful soluble oligomers and holes found within cell membranes.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

Procavea Biotech specializes in developing a drug delivery system based on non-viral protein cages for targeted therapeutic applications.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Transpire Bio is a biotechnology platform focused on the development of inhaled therapeutics aimed at improving healthcare outcomes globally. The company specializes in the commercialization of lower-cost generic alternatives for injectable drugs, utilizing innovative delivery methods to enhance patient experience by providing painless administration. Transpire Bio's product portfolio includes medicines and inhalation therapies targeting both lung diseases and systemic conditions, reflecting its commitment to addressing a wide range of health challenges through advanced biopharmaceutical solutions.

PlasNifix is a technology company that has developed a novel process for nitrogen fixation, using plasma assistance to enable the production of ammonia and other nitrogen-containing compounds at lower temperatures and with significantly less energy. This innovative method relies on proprietary catalysts and plasma generators, facilitating a more efficient and sustainable production process that can help agricultural and fertilizer industries reduce their dependence on fossil fuels.

Gaia Tech innovatively converts agricultural sidestreams into bio-compounds and high-value ingredients, primarily focusing on olive waste products. Its scalable technology enables cost-effective production of antioxidants, biochar, activated carbon, biogas, and other valuable resources for cosmetics, food, and feed industries. This approach helps reduce environmental footprint while creating new value streams for the primary sector.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

ASTRA Therapeutics is a medication development company focused on creating innovative therapies for parasitic diseases. Utilizing advanced science and technology, the company develops precision-engineered drugs to combat a wide range of parasitic disorders, including malaria, cryptosporidiosis, and toxoplasmosis. Its mission is to address the global health burden posed by these conditions by bringing effective treatment candidates to market.

metaLead Therapeutics is developing a short peptide medication designed to revolutionize the treatment of metal-related diseases. Its approach involves selectively capturing toxic metals for targeted removal, while preserving essential ones, thereby improving efficacy and minimizing side effects.

Tandem Therapeutics is a biopharmaceutical company dedicated to pioneering treatments for fibrotic diseases. It focuses on the extracellular matrix, a complex network of proteins that surrounds cells, and develops peptide therapeutics, known as Matrix Targeting Peptides (MTPs), to target and treat the extracellular matrix barrier. This innovative approach aims to provide more precise and effective treatments for patients suffering from fibrotic conditions, including cancers and organ fibrosis.

Adularia is a microbial-based therapy for Colorectal cancer.

Aukera Therapeutics is a biotechnology company focused on developing innovative therapeutics targeting the mTOR protein pathway. Its primary focus lies in treating diseases such as cancer and neurodegenerative disorders.

Biosimo is a startup focused on developing processes to produce bio-based platform chemicals. Its innovative approach involves using ethanol derived from biomass and waste to create sustainable alternatives to fossil fuel-based chemicals, catering primarily to the chemical, pharmaceutical, and material industries.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on Endometriosis. The company aims to accelerate the path toward a cure for endometriosis by addressing significant healthcare requirements and advancing novel ideas in women's health. FimmCyte's mission is to empower women to take control of their health and meet their unmet medical needs through cutting-edge treatments.

Suri Biotech is a biotechnology company specializing in the development of targeted bacterial strains aimed at alleviating bloating and intestinal discomfort. Its proprietary strains reduce hydrogen gas production by intestinal microorganisms, with potential applications in various functional gastrointestinal disorders.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

Reactive Illumination proposes an innovative green way to convert any organic waste (biowaste, tyres etc.) to mainly solid carbon and energy-efficient gases like H2, CH4, etc. within seconds without any chemicals that can be collected and used.

Avelo focuses on saving lives through swift and precise infectious disease diagnoses in primary care settings. It specializes in manufacturing breath aerosol diagnostic equipment designed to enhance tuberculosis diagnosis via a non-invasive, painless breath collection device. This enables faster, accurate diagnoses using existing PCR testing infrastructure, facilitating earlier appropriate treatment and rapid patient referral.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Biosimo is a startup focused on developing processes to produce bio-based platform chemicals. Its innovative approach involves using ethanol derived from biomass and waste to create sustainable alternatives to fossil fuel-based chemicals, catering primarily to the chemical, pharmaceutical, and material industries.

inSEIT provides enzyme immobilization services for industrial biocatalysis, covering the full workflow from matching enzymes with supports to application development and process scale-up. It combines predictive bioinformatics, experimental screening, and data-driven optimization to help chemical and bioprocess businesses implement biocatalysis, improve catalyst stability, enable reuse, and scale production efficiently.

Adularia is a microbial-based therapy for Colorectal cancer.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Adaptyv Bio is a biotechnology company focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company's innovative technology aims to identify new antibodies for the treatment of various diseases by bridging the gap between computational predictions and experimental validation. Through its advanced methodologies, Adaptyv Bio seeks to enhance the efficacy of therapeutic interventions, ultimately improving patient outcomes.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

Oncobit specializes in developing precise diagnostic tests and monitoring tools to enhance personalized cancer care. Its platform analyzes patient samples, offering clinicians advanced molecular insights to optimize therapy management.

Bottneuro is a company focused on developing innovative therapies for early to moderate-stage Alzheimer's Disease patients. Utilizing its proprietary NENI technology platform, Bottneuro creates non-invasive stimulation protocols that target neurons and glial cells in the brain. In addition to its work in Alzheimer's treatment, the company has developed a brain therapy system designed to alleviate chronic neuropathic pain. This system employs plant-based components and features a 3D printed cap that allows for continuous monitoring and targeted delivery of active substances within the body. By addressing the specific needs of patients with early to mild Alzheimer's disease, Bottneuro aims to enhance their quality of life through improved treatment options and medical care.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers aimed at diagnosing neurological disorders. Utilizing advanced technology, Nemosia creates tracers that facilitate the early detection of neurodegenerative diseases by visualizing N-methyl-D-aspartate (NMDA) receptors in the brain. This innovative approach allows for timely intervention, enabling patients to take proactive measures against neurological conditions. Through its specialized PET imaging capabilities, Nemosia contributes to improved diagnostic accuracy and better patient outcomes in the field of neurology.

ArcoScreen is a Swiss medtech company developing a microfluidic discovery platform for drug screening that targets membrane receptors, notably G-protein coupled receptors. The platform blends a lab-on-chip system with biological assays to quantify GPCR activation in primary mammalian cells, including guanosine 5'-O-(3-thiotriphosphate)-based functional readouts, and supports both ready-to-use and custom stable cell lines. This approach enables pharmaceutical researchers to investigate receptor signaling, identify drug modes of action, and perform in-vitro screenings directly on patient-derived cells. By enabling faster, more predictive screenings, ArcoScreen aims to reduce clinical attrition and accelerate the development of therapeutic candidates with improved translational relevance.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

Bionomous develops innovative devices that automatically inspect and sort miniature biological entities using advanced micro-engineering design and machine learning methods. These devices facilitate studies in genetics, development, behavioral biology, toxicology, and other biotech applications.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

Bloom Biorenewables Ltd is a Swiss company established in 2019, specializing in the development of innovative technologies that convert wood and agricultural waste into renewable materials as substitutes for petroleum-based products. The company focuses on producing bio-based materials for various sectors, including fragrances, plastics, and textiles, thereby offering sustainable alternatives to fossil fuels. By introducing a novel approach to the production of biorenewable products and fuels, Bloom Biorenewables aims to make a significant impact in promoting the use of sustainable resources and addressing climate change challenges.

LifeMatrix is a biotechnology company focused on the development of biomimetic implants and bio-engineering technologies aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company specializes in human cell-derived, off-the-shelf tissue-engineered implants that integrate with the patient's body post-implantation, allowing them to grow and regenerate. This innovative approach addresses the limitations of traditional implants, promoting faster recovery and improved outcomes for patients. LifeMatrix's technology is supported by over 20 years of research, resulting in more than 100 peer-reviewed publications and extensive preclinical studies demonstrating safety and efficacy, paving the way for clinical applications. The company's advancements are bolstered by various national and international research grants, reflecting its commitment to transforming the field of regenerative medicine.

Bionomous develops innovative devices that automatically inspect and sort miniature biological entities using advanced micro-engineering design and machine learning methods. These devices facilitate studies in genetics, development, behavioral biology, toxicology, and other biotech applications.

Nutrix is a Swiss health-technology company focused on prevention and precision medicine. It develops a non-invasive nanosensor placed on the tooth to measure glucose levels in saliva, with data transmitted to an external application. The sensor tracks food intake and provides dietary guidance to help prevent diabetes. The company combines artificial intelligence with wearables and human care to deliver cost-effective prevention and healthcare programs, including digital coaching and telemedicine, enabling caregivers to monitor patients remotely and reduce routine doctor visits. In 2025 Nutrix expanded its offering with CortiSense, a cortisol monitoring sensor, reflecting its move into non-invasive hormonal monitoring. Based in Basel, Switzerland, Nutrix provides an integrated solution of sensors, software, and care services.

Flowbone develops and promotes an injectable biomaterial for minimally invasive augmentation of fragile bones at high risk of fracture. Its treatment strengthens bone without impeding mechanics or blood flow, aiming to improve independence and quality of life among the elderly by preventing fragility fractures.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

OptiChroniX is a Swiss-based digital health solutions company focused on enhancing brain health through early intervention. The company specializes in developing digital therapeutics that integrate biomedical, behavioral, computing, and engineering research. These interventions are deployed on smartphones and utilize data from wearable devices to personalize and monitor patients' health progress. OptiChroniX aims to improve clinical outcomes, quality of life, and cost-effectiveness by providing tailored coaching to enhance health literacy, medication adherence, and address modifiable risk factors associated with cognitive decline in conditions like Alzheimer’s disease and related comorbidities.

Terapet specializes in advanced proton therapy for cancer treatment. Founded by physicists Christina Vallgren, Marcus Palm, and Professor Raymond Miralbell from Geneva University Hospitals, the company offers precise radiotherapy that minimizes harm to healthy cells. Incorporated in 2019, Terapet is based in Geneva, Switzerland.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Endotelix is a Swiss biotechnology company and a spin-off from the University of Geneva focused on antiphospholipid syndrome. It develops diagnostic tests and treatment options, aiming to deliver fast, sensitive solutions for the condition. The company provides diagnostic tools, therapies, and supports clinical research to assist clinicians in diagnosing antiphospholipid syndrome and identifying effective treatments.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Founded in 2019, Swiss Medical Union specializes in developing and manufacturing advanced bioreactor systems for testing new medical products' interaction, efficiency, and safety using human organ and tissue models. The company offers a software suite to simulate organ activity, analyze product-organ interactions, and monitor effects in real-time. Additionally, they provide clinical testing services to hospitals, healthcare institutions, and international facilities.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

MaxWell Biosystems is a neuroscience-focused electronics and biotechnology company that develops instrumentation and solutions to advance neuroscience research and accelerate preclinical drug discovery. It provides functional cell imaging and electrophysiology platforms to study cellular function and network activity. The flagship MaxOne platform is a CMOS-based high-density microelectrode array that records and stimulates electrogenic cells in vitro, featuring thousands of electrodes, low-noise readout channels and multiple stimulation channels to enable single-cell and network parameter extraction for phenotypic screening and drug toxicity and efficacy testing. The integrated platform combines a sensor chip, acquisition hardware and software to deliver accurate results and speed up the characterization of cell function from months to weeks. The company, founded in 2016, is based in Zurich, Switzerland.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Bloom Biorenewables Ltd is a Swiss company established in 2019, specializing in the development of innovative technologies that convert wood and agricultural waste into renewable materials as substitutes for petroleum-based products. The company focuses on producing bio-based materials for various sectors, including fragrances, plastics, and textiles, thereby offering sustainable alternatives to fossil fuels. By introducing a novel approach to the production of biorenewable products and fuels, Bloom Biorenewables aims to make a significant impact in promoting the use of sustainable resources and addressing climate change challenges.

KaleiBox is a company based in Zurich, Switzerland, specializing in the development of three-dimensional optical imaging devices specifically designed for small-animal imaging. It offers two main products: the standalone-mode KaleiBox and a hybrid-mode KaleiBox, both of which facilitate fluorescence tomography with an emphasis on compact hardware design and advanced software. The company's devices serve various applications, including research laboratories, biotechnological industries, agricultural diagnostics, and image-guided surgical procedures. Drawing inspiration from the kaleidoscope, KaleiBox focuses on versatility and portability, aiming to enhance the current workflow in 3D fluorescence imaging, particularly for preclinical studies.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Microcaps develops microencapsulation technology that protects and controls the release of active ingredients in pharmaceuticals, probiotics, and cosmetic formulations. Leveraging microfluidics and step emulsification, the company produces monodisperse microcapsules and microparticles at scale, enabling precise size control, dosing, and greater stability. Its platform supports liquid oil core microcapsules with natural alginate shells, improving throughput without quality loss. Based in Zurich, Switzerland, Microcaps targets applications across drug delivery, probiotic encapsulation, and fragrance or cosmetic encapsulation, offering automated encapsulation production capable of high-throughput manufacturing for complex formulations.

Endotelix is a Swiss biotechnology company and a spin-off from the University of Geneva focused on antiphospholipid syndrome. It develops diagnostic tests and treatment options, aiming to deliver fast, sensitive solutions for the condition. The company provides diagnostic tools, therapies, and supports clinical research to assist clinicians in diagnosing antiphospholipid syndrome and identifying effective treatments.

Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Mitoscreening platform (MSP) is used to screen metabolism-targeting anti-cancer drugs to discover.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Evictas is a biotechnology company.

Viventis Microscopy develops an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples, such as embryos and organoids. The company provides both the hardware and custom microscope control software, facilitating advanced imaging capabilities for researchers and organizations. By enabling detailed observation of delicate biological structures, Viventis Microscopy supports efforts in drug development and other scientific endeavors, helping to accelerate research and enhance the understanding of complex biological processes.

Endotelix is a Swiss biotechnology company and a spin-off from the University of Geneva focused on antiphospholipid syndrome. It develops diagnostic tests and treatment options, aiming to deliver fast, sensitive solutions for the condition. The company provides diagnostic tools, therapies, and supports clinical research to assist clinicians in diagnosing antiphospholipid syndrome and identifying effective treatments.

Prolongate is a protein drugs and biotech company.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

BIOMEM

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.